Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810518 · ClinicalTrials.gov registry record
ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
A clinical trial of Inflammatory Bowel Syndrome and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), sponsored by American Laboratory Products Company.
- Recruiting
- Registry status
- 220
- Enrollment target
- 3
- Study locations
NCT06810518 is a study of Inflammatory Bowel Syndrome and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) that is actively recruiting participants, run by American Laboratory Products Company. The registered enrollment target is 220 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06810518, a study of Inflammatory Bowel Syndrome and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), is actively recruiting participants, sponsored by American Laboratory Products Company.
- RECRUITING
- Registry status
- 220 participants
- Enrollment target
- 3
- Study locations
Study Summary
The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC), as well as aid in the differentiation of IBD from Irritable Bowel Syndrome (IBS) when used in conjunction with other diagnostic testing and the total clinical picture. The goal of the study is to generate data to support positive and negative predictive value of the ALPCO Calprotectin assay in patients with signs and symptoms of IBS or IBD.
Conditions Studied
Interventions
- DEVICE ALPCO Calprotectin CLIA
Study Locations (3)
Florida
- Med-Care Research Corp - Miami
New Hampshire
- ALPCO - Salem
Ohio
- Gastro Intestinal Research Institute of Northern Ohio, - Westlake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06810518
The ClinicalTrials.gov registry entry for NCT06810518 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Laboratory Products Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammatory Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which ALPCO Calprotectin CLIA is the first listed.
NCT06810518 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, New Hampshire, Ohio.
Frequently Asked Questions
What is clinical trial NCT06810518 about?
NCT06810518 is a clinical study titled "ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool". The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases ...
What is the current status of trial NCT06810518?
This trial is currently recruiting. The enrollment target is 220 participants. The study started on 2025-03-25. Estimated completion is 2026-12-31.
What conditions does trial NCT06810518 study?
This clinical trial studies the following conditions: Inflammatory Bowel Syndrome, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis).
What interventions are being tested in trial NCT06810518?
The interventions under investigation include: ALPCO Calprotectin CLIA (DEVICE).
Who is sponsoring clinical trial NCT06810518?
This trial is sponsored by American Laboratory Products Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810518 being conducted?
This trial has 3 study locations across Florida, New Hampshire, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Inflammatory Bowel Syndrome
All registered trials for this condition
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.